Opinion
Video
Achieving Superior Treatment Durability and Outcomes In Neovascular AMD and DME
Author(s):
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
0:00 Introduction
0:56 Need for durable treatments in nAMD and DME
4:29 Mechanism of faricimab
7:14 Highlights from clinical trials for faricimab
10:33 Post hoc analyses of faricimab clinical trials
16:24 Factors affecting retreatment decision
19:28 Durability data for faricimab
23:22 Experience with faricimab
29:06 Choosing between faricimab and high-dose aflibercept
32:51 Final remarks
Related Videos
Related Content
